GlassScriptPhysician profile
Yale D Podnos
NPI 1649215146
$12,311.28
in general payments reported to CMS, 2019-2025
20 companies · $9,333 in 2025
The $9,333 reported for 2025 was more than what 95% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.76 · 2022: $246 · 2023: $605 · 2024: $2,069 · 2025: $9,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,875 · Food and Beverage: $2,276 · Honoraria: $1,350 · Travel and Lodging: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,875.00 |
| Food and Beverage | $2,275.89 |
| Honoraria | $1,350.00 |
| Travel and Lodging | $507.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $8,907.52 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $1,350.00 | 2024 | |
| Beigene USA, INC. | $609.10 | 2023-2024 | Brukinsa |
| Beone Medicines USA, INC. | $335.42 | 2025 | Brukinsa, Tevimbra |
| Eagle Pharmaceuticals, INC. | $334.16 | 2022-2024 | |
| Pfizer INC. | $302.10 | 2022-2024 | |
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Lilly USA, LLC | $75.08 | 2023-2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $69.18 | 2021-2024 | |
| Progenics Pharmaceuticals, INC. | $32.15 | 2022 | |
| Glaxosmithkline, LLC. | $31.01 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.11 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.14 | 2022 | |
| Seagen INC. | $18.81 | 2021 | |
| Abbvie INC. | $18.71 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $18.18 | 2025 | Pyrukynd |
| Novocure INC. | $18.02 | 2024 | Optune Lua (Novottf-200t) |
| Janssen Biotech, INC. | $15.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.22 | 2022 | |
| Incyte Corporation | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yale Podnos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.